A combination of Dinutuximab and anti-CD47 antibodies results in the recruitment of tumor-associated macrophages (TAMs) to mediate robust and durable anti-tumor responses, which might expand the clinical use of anti-GD2 mAbs to other GD2+ diseases beyond NB (77). The gene discussed is CD47; the disease is neoplasm.